Ubs Group Ag Travere Therapeutics, Inc. Transaction History

Ubs Group Ag

$611 Billion
Q3 2025

A detailed history of Ubs Group Ag transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 493,073 shares of TVTX stock, worth $17 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

493,073

Previous 650,281 24.18%

Holding current value

$17 Million

Previous $9.62 Million 22.44%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$14.61 - $27.31 $2.3 Million - $4.29 Million	-157,208 Reduced 24.18%	493,073 $11.8 Million
Q2 2025 Aug 14, 2025	SELL	$13.49 - $21.54 $738,064 - $1.18 Million	-54,712 Reduced 7.76%	650,281 $9.62 Million
Q1 2025 May 13, 2025	SELL	$17.07 - $23.75 $74,493 - $103,645	-4,364 Reduced 0.62%	704,993 $12.6 Million
Q4 2024 Feb 14, 2025	BUY	$13.65 - $19.85 $5.23 Million - $7.6 Million	383,122 Added 117.44%	709,357 $12.4 Million
Q3 2024 Nov 14, 2024	BUY	$7.89 - $15.21 $1.54 Million - $2.96 Million	194,729 Added 148.08%	326,235 $4.56 Million

Q2 2024 Aug 13, 2024	SELL	$5.26 - $8.28 $1.27 Million - $2 Million	-241,105 Reduced 64.71%	131,506 $1.08 Million
Q1 2024 May 13, 2024	BUY	$7.18 - $9.82 $1.41 Million - $1.93 Million	196,131 Added 111.13%	372,611 $2.87 Million
Q4 2023 Feb 09, 2024	BUY	$5.44 - $9.5 $561,924 - $981,302	103,295 Added 141.14%	176,480 $1.59 Million
Q3 2023 Nov 09, 2023	SELL	$7.64 - $17.25 $474,726 - $1.07 Million	-62,137 Reduced 45.92%	73,185 $654,000
Q2 2023 Aug 11, 2023	BUY	$15.3 - $22.61 $145,916 - $215,631	9,537 Added 7.58%	135,322 $2.08 Million
Q1 2023 May 12, 2023	SELL	$17.82 - $22.89 $1.5 Million - $1.93 Million	-84,329 Reduced 40.13%	125,785 $2.83 Million
Q4 2022 Feb 08, 2023	BUY	$18.47 - $26.14 $3.1 Million - $4.39 Million	167,838 Added 397.01%	210,114 $4.42 Million
Q3 2022 Nov 10, 2022	SELL	$22.91 - $28.63 $1.36 Million - $1.7 Million	-59,490 Reduced 58.46%	42,276 $1.04 Million
Q2 2022 Aug 10, 2022	SELL	$20.94 - $30.01 $1.08 Million - $1.55 Million	-51,550 Reduced 33.62%	101,766 $2.47 Million
Q1 2022 May 16, 2022	SELL	$23.61 - $30.6 $257,112 - $333,234	-10,890 Reduced 6.63%	153,316 $3.95 Million
Q4 2021 Feb 14, 2022	BUY	$24.34 - $31.17 $3.98 Million - $5.1 Million	163,607 Added 27313.36%	164,206 $5.1 Million
Q3 2021 Nov 15, 2021	SELL	$12.98 - $25.03 $178,150 - $343,536	-13,725 Reduced 95.82%	599 $14,000
Q2 2021 Aug 13, 2021	SELL	$14.11 - $26.4 $507,367 - $949,291	-35,958 Reduced 71.51%	14,324 $209,000
Q1 2021 May 12, 2021	BUY	$23.37 - $31.77 $1.14 Million - $1.55 Million	48,860 Added 3436.01%	50,282 $1.26 Million
Q4 2020 Feb 11, 2021	BUY	$19.17 - $27.87 $27,259 - $39,631	1,422 New	1,422 $38,000

Others Institutions Holding TVTX

# of Institutions

269

Shares Held

100M

Call Options Held

2.36M

Put Options Held

955K

View Full List

About Travere Therapeutics, Inc.

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $2.21B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

More about TVTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account